lets take a look at the warrants with arj in this matter from what i read after conversion the warrants would have giving them 925,925,925 shares but instead they amended it to were they only got 500,000,000 shares for the same money . that is 425,925,925 shares less then the original amount of the warrant after conversion. now this was at a fixed exercise price of $.0025 per share. what is wrong with that?
now yes he purchased them at .0025 and is making a profit there is nothing wrong with that. now you purchased shares at .0025 and now they are up and you are making money on your investment. So why would it not be fare for him to make the same money on his investment but at a higher stack in the game. he is taking the same risk as we are if they share price falls so dose his profit margin just as yours dose .I think that is fare dont you? well we all invest to make money dont we ? So with that said he invested to make money as well but at higher stacks then we do so he will make more then us and it just draws more attention to what he owns then what the average investor owns all is far in love and war. Also for the rest of the shares he owns he bought them out of his own pocket just as you and i did. so i think it is fare and nothing wrong with that. Gains in your account also mean gains in his account it is only fare.
Item 4. Purpose of Transaction ARJ previously reported its acquisition of a significant position in the Issuer’s Common Stock (“Transaction”) in a Schedule 13D filing, dated February 8, 2019. The within report is necessitated by amendments to and exercise of certain of the documents and instruments described in such filing, as well as a new subscription for shares of Common Stock made by ARJ. The Transaction was made pursuant to a Securities Purchase Agreement (“SPA”), dated February 8, 2019, a Convertible Promissory Note (“Note”) of even date, a Warrant (“Warrant”) of even date and a Registration Rights Agreement (“RRA”) of even date, all by and between the same parties. ARJ is not acting as part of a “group” as defined under Rule 13d-5(b). The SPA contains no arrangements granting ARJ any rights of representation on or election to Issuer’s board of directors. All calculations herein specifically exclude 500,000,000 shares of Common Stock issuable upon exercise of the Warrant which contains a prohibition on exercise based upon stock ownership which is waivable by the holder of the Warrant.
CUSIP NO. 94762T107 Page 5 of 7 On May 30, 2019, the Note was amended by letter agreement (“Letter Agreement”) to provide for a fixed exercise price of $.0025 per share, and such Note was exercised in full by ARJ on such date resulting in the issuance of 512,333,333 shares of Common Stock. Also on May 30, 2019, the Warrant was amended by such Letter Agreement to provide that it is exercisable as to an aggregate of 500,000,000 shares of Issuer Common Stock, not the original amount of 925,925,925 shares. The RRA was also amended on such date to provide for, among other things, an extension of time within which the Company has to file one (1) or more registration statements. Finally, on May 30, 2019, ARJ and the Company also entered into a new Securities Purchase Agreement (“New SPA”), pursuant to which ARJ purchased an aggregate of 41,666,666 shares of Common Stock for an aggregate consideration of $500,000.00 The foregoing descriptions of the New SPA, Letter Agreement and Amendment to the RRA are qualified in their entirety by reference to the full text of such documents which are attached as Exhibits 99.1 through 99.3 hereto and are incorporated herein by this reference. Neither ARJ nor Garnock does, at present, seek control of the Issuer and ARJ has acquired the Common Stock for investment purposes. In pursuing such investment purposes, ARJ may further purchase, hold, vote, trade, dispose or otherwise deal in the Common Stock at times, and in such manner, as it deems advisable to benefit from changes in market prices of the Common Stock, changes in the Issuer’s operations, business strategy or prospects, or from sale or merger of the Issuer. To evaluate such alternatives, ARJ routinely monitors the Issuer’s operations, prospects, business development, management, competitive and strategic matters, capital structure, and prevailing market conditions, as well as alternative investment opportunities, its liquidity requirements and other investment considerations. Consistent with its investment research methods and evaluation criteria, ARJ may discuss such matters with management or directors of the Issuer, other shareholders, industry analysts, existing or potential strategic partners or competitors, investment and financing professionals, sources of credit and other investors. Such factors and discussions may materially affect, and result in, ARJ’s modifying its ownership of the Common Stock, exchanging information with the Issuer pursuant to appropriate confidentiality or similar agreements, proposing changes in the Issuer’s operations, governance or capitalization, or in proposing one or more of the other actions described in subsections (a) through (j) of Item 4 of Schedule 13D. ARJ and Garnock each reserves the right to formulate other plans and/or make other proposals, and take such actions with respect to its investment in the Issuer, including any or all of the actions set forth in paragraphs (a) through (j) of Item 4 of Schedule 13D, or acquire additional Common Stock or dispose of all or part of the Common Stock beneficially owned by them, in the public market or privately negotiated transactions. ARJ and Garnock may, at any time reconsider and change its plans or proposals relating to the foregoing.
Market Data 
Markets 
AI
